Recursion and Faro Health Partner to Reimagine Clinical Trial Design with AI

Faro Health has partnered with Recursion to streamline clinical protocol design using Faro's AI-driven platform.

Recursion, a clinical-stage TechBio company leveraging large-scale biological and chemical datasets for drug discovery, aims to integrate Faro's platform to optimize protocol designs for its drug development programs. The partnership aligns with Recursion’s focus on applying AI/ML across its pipeline, which includes over 10 clinical and preclinical programs following its merger with Exscientia in 2024.

Faro’s platform is designed to reduce trial complexity and costs by transitioning protocol design from document-based to data-driven processes. Its capabilities have been demonstrated in workshops, where it was shown to help sponsors reimagine trial protocols by focusing on essential data-generating assessments, minimizing unnecessary measurements, and optimizing schedules based on biological plausibility. For instance, the platform has supported decisions to limit assessments such as complete blood counts or physical exams to the most critical time points, reducing trial burdens by up to 47 participant hours per protocol while preserving trial integrity and regulatory compliance.

Faro Health's Study Designer

Recursion plans to use Faro’s software not only to refine study protocols but also to automate tasks such as configuring electronic data capture (EDC) systems, replacing traditionally manual processes. The structured study definitions generated through Faro's platform are expected to enhance both the design and operational phases of clinical trials.

Faro Health develops cloud-based software for modernizing clinical trial design. Recursion operates the Recursion Operating System, combining machine learning and large-scale experiments to accelerate drug discovery and development. The companies view this partnership as a step toward reducing the time and costs of clinical research while improving outcomes.